Plain-English translation of NCT05909501 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at a better way to evaluate the health of older adults with acute myeloid leukemia (AML) before they start treatment. Instead of deciding on a treatment plan based only on a patient's age, doctors want to understand the patient's overall physical and mental fitness—what researchers call 'physiologic age.' The study will track how well patients do on their chosen treatment and whether this new evaluation method helps predict who will have fewer side effects and better outcomes.
Right now, doctors sometimes make treatment decisions for older patients based mainly on their calendar age, which doesn't always reflect how healthy someone actually is. This study wants to find out if a more complete health assessment can better predict which patients will tolerate treatment well and live longer.
You likely qualify if…
You likely don't qualify if…
As a participant, you would complete detailed health evaluations and questionnaires at the start of the study to capture your overall health status. Then, researchers would follow your progress as you receive your chosen AML treatment (either intensive chemotherapy or a gentler approach), monitoring how you respond, any side effects you experience, and your long-term survival. The study involves about 100 patients and is designed to help doctors better predict treatment outcomes.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Bristol-Myers Squibb
Enrollment target
~100 participants
Started
October 2023
Primary completion
December 2026
Age range
50 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Colleen Redlinger
Abramson Cancer Center at Penn Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.